| (V295) |
Genetische und pharmakologische Inaktivierung der PI3 Kinase Isoform p110α schützen vor experimenteller pulmonaler Hypertonie |
|
E. M. Berghausen, W. Janssen, M. Vantler, M. A. Alcazar, H. ten Freyhaus, A. Klinke, J. J. Zhao, R. Schermuly, S. Rosenkranz (Köln, Gießen; Boston, US) |
| (V296) |
Folic acid partially prevents hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy |
|
D. Kracun, I. Kanchev, F. Rieß, A. Görlach (München) |
| (V297) |
Dexamethasone induces pulmonary vascular remodeling via activation of NADPH oxidases and the HIF system |
|
D. Kracun, I. Kanchev, F. Rieß, A. Görlach (München) |
| (V298) |
The PAR-4 thrombin receptor is a novel mediator of diabetic vascular remodeling |
|
A. Fender, G. Pavic, B. H. Rauch, K. Schrör, J. W. Fischer (Düsseldorf, Greifswald) |
| (V299) |
The calcium-binding protein S100A6 is an essential regulator of vascular remodeling |
|
C. Lerchenmüller, J. Heißenberg, I. Krämer, J. Ritterhoff, H. A. Katus, P. Most (Heidelberg) |
| (V300) |
Regulation of vascular smooth muscle cell proliferation by DNA-dependent protein kinase through the orphan nuclear receptor NOR1 |
|
S. Medunjanin, S. Brecht, J. M. Daniel, F. Burgbacher, D. G. Sedding, R. H. Strasser, R. Braun-Dullaeus (Magdeburg, Gießen, Dresden) |